Q1 2025 Earnings Conference Call April 29, 2025 6:45 AM ETCompany ParticipantsAndy Barnett - Head of IRPascal Soriot ...

AstraZeneca posts Q1 revenue of $13.59 billion and a strong EPADS beat; oncology leads growth as China's tax probe and halts ...

The headline numbers for Astrazeneca (AZN) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street ...

AstraZeneca’s AZN first-quarter 2025 core earnings of $1.24 per American depositary share (ADS) beat the Zacks Consensus ...

Investing.com -- AstraZeneca (LON: AZN ) (ST: AZN) shares fell more than 3% Tuesday after the drugmaker missed first-quarter revenue expectations, with underperformance in key cancer and respiratory ...

SIGNIFICANT EVENTS DURING 1 JANUARY - 31 MARCH 2025Iconovo and Lonza have entered a collaboration to develop spray-dried formulations of an intranasal biologic drug for Iconovo's proprietary intranasa ...

AZN's key medicines, mainly cancer drugs, Lynparza, Tagrisso and Imfinzi, are expected to have driven the company's top line.

In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ:AZN) stands against other best UK stocks to invest in. Like most of the world, the United Kingdom is also facing ...

My AstraZeneca (LSE: AZN) shares have made moderate gains of 7% since Christmas — slightly above the 5% gain of the FTSE 100. A £10,000 investment back then would have returned about £755 ...

Breztri Aerosphere (budesonide/glycopyrrolate/formoterol fumarate) can cause side effects that range from mild to serious. If side effects from Breztri become ...

AstraZeneca, one of the largest companies in Britain, was the biggest loser in the FTSE 100 yesterday, slumping 6.8pc, or 707p, to 9667p. It was followed by rival GSK, which tumbled 5.7 per cent ...

UK retail investors upped their purchases of stocks substantially as Trump’s trade war crashed markets. The global trade war has kicked into a new gear and it’s bad news for some of the FTSE ...